Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel + camrelizumab + apatinib for advanced biliary tract cancer
ChiCTR2100041608Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel, camrelizumab and Rivoceranib in biliary cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
paclitaxelcamrelizumabRivoceranib
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2100041608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041608.